233 results on '"Kelly, Ronan J."'
Search Results
2. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
3. Mapping fireline intensity and flame height of prescribed gorse wildland fires
4. A blood-based circulating microbial metagenomic panel for early diagnosis and prognosis of oesophageal adenocarcinoma
5. Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma
6. Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer
7. Prognostic and predictive biomarkers for response to neoadjuvant chemoradiation in esophageal adenocarcinoma
8. Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis
9. Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection
10. First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.
11. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial
12. Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non–Small-Cell Lung Cancer
13. Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy
14. Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors
15. Sitravatinib combined with PD-1 blockade enhances cytotoxic T-cell infiltration by M2 to M1 tumor macrophage repolarization in esophageal adenocarcinoma.
16. The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis
17. Scientific Advances in Thoracic Oncology 2016
18. Role of Immunotherapy in Gastroesophageal Cancers—Advances, Challenges and Future Strategies.
19. Targeting the Hedgehog Pathway Using Itraconazole to Prevent Progression of Barrettʼs Esophagus to Invasive Esophageal Adenocarcinoma
20. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
21. The emerging role of immunotherapy for esophageal cancer
22. The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation
23. Age-associated dysregulation of microglial activation is coupled with enhanced blood-brain barrier permeability and pathology in APP/PS1 mice
24. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care
25. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial
26. Challenges, Perceptions, and Readiness of Oncology Clinicians for the MACRA Quality Payment Program
27. Classical activation of microglia in CD200-deficient mice is a consequence of blood brain barrier permeability and infiltration of peripheral cells
28. Immunotherapy in Upper GI Malignancies
29. Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC
30. Scientific Advances in Lung Cancer 2015
31. The Texas Immuno-Oncology Biorepository, a statewide biospecimen collection and clinical informatics system to enable longitudinal tumor and immune profiling.
32. Immune Checkpoint Inhibitors: Changing the Treatment Landscape in Esophagogastric Adenocarcinoma.
33. Targeting the Immune System in Non–Small-Cell Lung Cancer: Bridging the Gap Between Promising Concept and Therapeutic Reality
34. CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat model.
35. Multi-center matched cohort study of convalescent plasma for hospitalized patients with COVID-19.
36. The Updated Overall Survival and Genomic Analysis from a Single-Arm Phase 2 Study of Dabrafenib plus Trametinib in Patients with BRAF V600E Mutant Metastatic Non-Small Cell Lung Cancer
37. Axitinib—a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor
38. Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief Report
39. Chemotherapeutic and Targeted Strategies for Locally Advanced and Metastatic Esophageal Cancer
40. Antiangiogenesis Induced Tumor Cavitation in Lung Cancer
41. Metastatic Phyllodes Tumor Causing Small-Bowel Obstruction
42. Current Strategies Using Hepatic Arterial Infusion Chemotherapy for the Treatment of Colorectal Cancer
43. Targeting the Hedgehog Pathway Using Itraconazole to Prevent Progression of Barrett’s Esophagus to Invasive Esophageal Adenocarcinoma.
44. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin
45. Healthcare utilization and total costs of care among patients with advanced metastatic gastric and esophageal cancer.
46. A phase 1, dose-escalation/response-expansion study of oral ASP8273 in patients with non-small cell lung cancers with epidermal growth factor receptor mutations
47. Dabrafenib in BRAF V600E–Mutant Advanced Non-Small Cell Lung Cancer: an Open-label, Single arm, Multicenter, Phase 2 Trial
48. State of the art management of metastatic gastroesophageal cancer
49. From Molecular Classification to Targeted Therapeutics: The Changing Face of Systemic Therapy in Metastatic Gastroesophageal Cancer
50. Complications and Economic Burden Associated With Obtaining Tissue for Diagnosis and Molecular Analysis in Patients With Non–Small-Cell Lung Cancer in the United States.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.